Robert B Bhisitkul, MD
Ophthalmology · San Francisco
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 12
- 2 carriers
- Office
- 1
- Since medical school
- 34 years
- Stanford University School of Medicine, 1992
Offices
1 location · UCSF Medical Group Business Services · 1,533 clinicians in this group
Hospitals listed: UCSF Medical Center. That is not proof they admit you there this week.
Plans that list them
12 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Bhisitkul’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
12 of 12 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
California Medical Board record
Licence G84511 · Current
Licensed to practise in California · since 1998 · expires 2028-03-31 · Stanford University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Ophthalmology - Ophthalmology
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- UCSF Medical CenterSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsHome of UCSF Helen Diller Family Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 81% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 4.9 (3.79 to 6.02) · 7,590 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.8 (11.3 to 14.4) · 2,019 cases, Jan 2024 – Dec 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 139.4 (110.22 to 168.58) · 452 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.622, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.626, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.491, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.7 to 1) · 2,336 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for UCSF Medical Center
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 3 better, 5 the same, 3 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.9 (3.79 to 6.02) · 7,590 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.8 (11.3 to 14.4) · 2,019 cases | Worse | Jan 2024 – Dec 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 139.4 (110.22 to 168.58) · 452 cases | Better | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.622 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.626 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.491 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.7 to 1) · 2,336 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.24 (0.58 to 1.9) · 4,689 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.05 (0.89 to 1.2) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.9 · 89 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.5 · 85 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.1 · 132 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.6 · 454 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 618 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 380 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.7 · 5,000 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.22 (0.06 to 0.38) · 15,965 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.05 to 0.35) · 17,859 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.85 (0 to 1.83) · 4,184 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2 (1.1 to 2.9) · 6,516 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.35 (4.49 to 10.21) · 3,989 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5 (3.22 to 6.77) · 4,087 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.95 (0.74 to 3.15) · 2,034 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.95 (0.63 to 1.28) · 15,431 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 399 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.899 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.689 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.224 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16 · 156 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20 · 564 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 60.3 · 160 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -9.7 · 550 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 44.1 · 660 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 667 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (4.8 to 6.7) · 2,019 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6 · 421 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.5 · 53 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 107 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.9 (11.3 to 17.1) · 3,247 cases | No different | Jan 2022 – Dec 2024 |
What patients said (3,181 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 71% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 78% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 50% |
| "YES", patients would definitely recommend the hospital | 81% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$127,456
Medicare paid this office $127,456 for 464 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Injection of drug into eye | 128 | $32,801 | $91 |
| Established patient complete exam of visual system | 212 | $17,635 | $67 |
| Injection of drug into eye | 92 | $13,862 | $70 |
| Imaging of retina | 301 | $13,104 | $23 |
| Established patient complete exam of visual system | 140 | $7,474 | $48 |
See all 12 services
| Injection of drug into eye | 128 | $32,801 | $91 |
| Established patient complete exam of visual system | 212 | $17,635 | $67 |
| Injection of drug into eye | 92 | $13,862 | $70 |
| Imaging of retina | 301 | $13,104 | $23 |
| Established patient complete exam of visual system | 140 | $7,474 | $48 |
| Imaging of retina | 229 | $5,737 | $16 |
| New patient complete exam of visual system | 37 | $3,084 | $83 |
| New patient complete exam of visual system | 46 | $3,016 | $66 |
| Established patient problem focused exam of visual system | 11 | $508 | $46 |
| Extended exam of the back part of the eye with retinal drawing | 16 | $330 | $21 |
| Extended exam of the back part of the eye with retinal drawing | 11 | $208 | $19 |
| Extended exam of the back part of the eye with optic nerve drawing | 13 | $161 | $12 |
Procedures year by year
| Procedure | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Injection of drug into eye | 494 | 467 | 576 | 516 | 473 | 561 |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
464 Original Medicare patients in 2024. Average age 76 · Under 65 6% · 85 and older 19% · Women 53% · Also on Medicaid 36% · Health risk score 1.61. Sicker patients than 9 in 10 peers; the typical ophthalmology clinician is at 1.16.
Conditions among them: High blood pressure 70% · Diabetes 36% · Chronic kidney disease 32% · Coronary heart disease 24% · Depression 21% · Cancer 16% · Atrial fibrillation 16% · Heart failure 15% · COPD 10% · Stroke 9% · Dementia 8%.
The office billed $1,396,510, Medicare allowed $175,629 and paid $127,456; for 2,127 services of 30 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 464 | 2,127 | 76 | 1.61 | $1,396,510 | $127,456 |
| 2023 | 474 | 2,094 | 76 | 1.58 | $1,348,766 | $125,974 |
| 2022 | 478 | 2,154 | 75 | 1.53 | $1,387,730 | $126,749 |
| 2021 | 445 | 2,269 | 76 | 1.62 | $1,630,115 | $140,147 |
| 2020 | 412 | 1,825 | 75 | 1.66 | $1,229,699 | $114,714 |
| 2019 | 501 | 2,249 | 75 | 1.70 | $1,344,959 | $133,063 |
| 2018 | 498 | 2,235 | 75 | 1.66 | $1,332,997 | $135,996 |
| 2017 | 469 | 1,997 | 75 | 1.69 | $1,234,313 | $130,540 |
| 2016 | 516 | 2,098 | 75 | 1.64 | $1,243,267 | $136,142 |
| 2015 | 510 | 1,971 | 74 | 1.61 | $1,241,484 | $142,366 |
| 2014 | 448 | 1,749 | 75 | 1.44 | $1,047,856 | $119,516 |
| 2013 | 391 | 1,774 | 75 | 1.42 | $1,112,527 | $134,797 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 8 services
| Injection of drug into eye | 112 | $34,812 | $74 |
| Established patient complete exam of visual system | 337 | $30,200 | $63 |
| Imaging of retina | 389 | $18,084 | $21 |
| New patient complete exam of visual system | 101 | $7,834 | $78 |
| Extended exam of the back part of the eye with retinal drawing | 62 | $1,121 | $18 |
| Established patient problem focused exam of visual system | 14 | $562 | $40 |
| 2d ultrasound scan of eye tissue and structures | 15 | $401 | $24 |
| Extended exam of the back part of the eye with optic nerve drawing | 31 | $367 | $12 |
2022: 8 services
| Injection of drug into eye | 124 | $41,264 | $80 |
| Established patient complete exam of visual system | 322 | $28,809 | $62 |
| Imaging of retina | 343 | $17,813 | $21 |
| New patient complete exam of visual system | 102 | $7,957 | $78 |
| Extended exam of the back part of the eye with retinal drawing | 73 | $1,358 | $19 |
| Extended exam of the back part of the eye with optic nerve drawing | 62 | $647 | $10 |
| 2d ultrasound scan of eye tissue and structures | 15 | $593 | $27 |
| Established patient problem focused exam of visual system | 12 | $465 | $39 |
2021: 8 services
| Injection of drug into eye | 121 | $45,653 | $79 |
| Established patient complete exam of visual system | 315 | $31,116 | $64 |
| Imaging of retina | 334 | $18,420 | $21 |
| New patient complete exam of visual system | 91 | $7,073 | $78 |
| Established patient problem focused exam of visual system | 31 | $1,328 | $42 |
| Extended exam of the back part of the eye with retinal drawing | 60 | $1,144 | $19 |
| 2d ultrasound scan of eye tissue and structures | 19 | $692 | $24 |
| Extended exam of the back part of the eye with optic nerve drawing | 56 | $608 | $11 |
2020: 11 services
| Injection of drug into eye | 99 | $32,388 | $85 |
| Established patient complete exam of visual system | 249 | $18,590 | $59 |
| Imaging of retina | 266 | $12,098 | $20 |
| Injection of drug into eye | 70 | $8,701 | $100 |
| Established patient complete exam of visual system | 71 | $5,392 | $73 |
| New patient complete exam of visual system | 45 | $3,421 | $76 |
| Imaging of retina | 111 | $3,057 | $24 |
| Established patient problem focused exam of visual system | 40 | $1,974 | $45 |
| Extended exam of the back part of the eye with retinal drawing | 38 | $790 | $20 |
| Extended exam of the back part of the eye with optic nerve drawing | 27 | $333 | $12 |
| Extended exam of the back part of the eye with retinal drawing | 11 | $215 | $20 |
2019: 8 services
| Injection of drug into eye | 109 | $45,312 | $92 |
| Established patient complete exam of visual system | 337 | $32,892 | $64 |
| Imaging of retina | 347 | $16,695 | $21 |
| New patient complete exam of visual system | 76 | $6,397 | $84 |
| Examination of eye by ophthalmoscope with retinal drawing | 78 | $2,536 | $19 |
| Established patient problem focused exam of visual system | 57 | $2,533 | $42 |
| Examination of eye by ophthalmoscope with retinal drawing | 63 | $1,881 | $16 |
| 2d ultrasound scan of eye tissue and structures | 16 | $846 | $28 |
2018: 9 services
| Established patient complete exam of visual system | 343 | $38,373 | $65 |
| Injection of drug into eye | 108 | $36,542 | $89 |
| Imaging of retina | 331 | $17,672 | $23 |
| New patient complete exam of visual system | 86 | $7,299 | $85 |
| Established patient problem focused exam of visual system | 64 | $3,085 | $42 |
| Examination of eye by ophthalmoscope with retinal drawing | 59 | $2,080 | $19 |
| Examination of eye by ophthalmoscope with retinal drawing | 49 | $1,258 | $15 |
| 2d ultrasound scan of eye tissue and structures | 18 | $960 | $40 |
| New patient problem focused exam of visual system | 20 | $878 | $44 |
2017: 10 services
| Injection of drug into eye | 104 | $37,279 | $89 |
| Established patient complete exam of visual system | 326 | $33,551 | $65 |
| Imaging of retina | 256 | $13,593 | $22 |
| New patient complete exam of visual system | 63 | $5,335 | $85 |
| Established patient problem focused exam of visual system | 85 | $4,551 | $44 |
| Examination of eye by ophthalmoscope with retinal drawing | 57 | $1,705 | $17 |
| Examination of eye by ophthalmoscope with retinal drawing | 37 | $1,195 | $19 |
| 2d ultrasound scan of eye tissue and structures | 13 | $1,141 | $48 |
| New patient problem focused exam of visual system | 15 | $575 | $38 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 12 | $490 | $41 |
2016: 10 services
| Injection of drug into eye | 110 | $39,152 | $92 |
| Established patient complete exam of visual system | 316 | $29,331 | $67 |
| Imaging of retina | 306 | $17,003 | $25 |
| Established patient problem focused exam of visual system | 124 | $7,813 | $44 |
| New patient complete exam of visual system | 73 | $6,122 | $84 |
| 2d ultrasound scan of eye tissue and structures | 24 | $1,790 | $45 |
| Examination of eye by ophthalmoscope with retinal drawing | 44 | $1,358 | $18 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 14 | $1,235 | $44 |
| Examination of eye by ophthalmoscope with retinal drawing | 38 | $1,093 | $16 |
| New patient problem focused exam of visual system | 23 | $962 | $42 |
2015: 11 services
| Injection of drug into eye | 96 | $33,751 | $90 |
| Established patient complete exam of visual system | 322 | $28,682 | $66 |
| Imaging of retina | 270 | $13,959 | $24 |
| New patient complete exam of visual system | 116 | $9,753 | $84 |
| Established patient problem focused exam of visual system | 105 | $8,405 | $44 |
| Examination of eye by ophthalmoscope with retinal drawing | 63 | $1,862 | $19 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 15 | $1,204 | $45 |
| 2d ultrasound scan of eye tissue and structures | 17 | $1,102 | $50 |
| Examination of eye by ophthalmoscope with retinal drawing | 22 | $610 | $18 |
| Photography of the retina | 14 | $471 | $22 |
| New patient problem focused exam of visual system | 11 | $464 | $42 |
2014: 8 services
| Injection of drug into eye | 89 | $33,079 | $92 |
| Established patient complete exam of visual system | 299 | $24,747 | $66 |
| Imaging of retina | 263 | $14,358 | $25 |
| Established patient problem focused exam of visual system | 102 | $9,162 | $47 |
| New patient complete exam of visual system | 80 | $6,979 | $87 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 17 | $890 | $44 |
| Examination of eye by ophthalmoscope with retinal drawing | 32 | $855 | $20 |
| Examination of eye by ophthalmoscope with retinal drawing | 26 | $640 | $17 |
2013: 10 services
| Injection of drug into eye | 86 | $33,520 | $91 |
| Established patient complete exam of visual system | 250 | $21,225 | $65 |
| Established patient problem focused exam of visual system | 141 | $15,504 | $45 |
| Imaging of retina | 180 | $10,189 | $24 |
| New patient complete exam of visual system | 84 | $6,398 | $76 |
| Examination of eye by ophthalmoscope with retinal drawing | 34 | $985 | $17 |
| Examination of eye by ophthalmoscope with retinal drawing | 31 | $930 | $17 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 20 | $821 | $37 |
| 2d ultrasound scan of eye tissue and structures | 13 | $688 | $46 |
| Photography of the retina | 18 | $365 | $19 |
Medicaid work
$170,692 in 2024
Medicaid paid $170,692 for 767 billed services this clinician did in 2024, up to 43 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Intravitreal injection of a pharmacologic agent (separate procedure) | 312 | $145,486 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 130 | $12,890 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 325 | $12,316 |
| 2024 | 767 | 3 | 43 | $170,692 |
| 2023 | 869 | 4 | 42 | $134,882 |
| 2022 | 1,072 | 4 | 42 | $83,728 |
| 2021 | 1,468 | 5 | 46 | $162,928 |
| 2020 | 911 | 4 | 41 | $102,861 |
| 2019 | 1,138 | 4 | 42 | $84,443 |
| 2018 | 1,509 | 4 | 49 | $93,795 |
See the largest Medicaid services in earlier years
2023
| Intravitreal injection of a pharmacologic agent (separate procedure) | 287 | $106,582 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 205 | $17,202 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 365 | $10,154 |
| OPH SVCS MEDICAL XM&EVAL COMPRE NEW PT 1/> VST | 12 | $945 |
2022
| Intravitreal injection of a pharmacologic agent (separate procedure) | 353 | $50,129 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 172 | $14,617 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 520 | $10,190 |
| Aflibercept injection | 27 | $8,791 |
2021
| Intravitreal injection of a pharmacologic agent (separate procedure) | 527 | $111,812 |
| Aflibercept injection | 38 | $22,336 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 249 | $16,277 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 624 | $10,600 |
| OFF/OP EST MAY X REQ PHY/QHP | 30 | $1,901 |
2020
| Intravitreal injection of a pharmacologic agent (separate procedure) | 328 | $82,740 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 432 | $8,494 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 139 | $8,080 |
| Aflibercept injection | 12 | $3,547 |
2019
| Intravitreal injection of a pharmacologic agent (separate procedure) | 360 | $64,657 |
| Aflibercept injection | 28 | $7,083 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 576 | $6,718 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 174 | $5,986 |
2018
| Intravitreal injection of a pharmacologic agent (separate procedure) | 329 | $68,990 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 519 | $15,348 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 563 | $5,902 |
| OFF/OP EST MAY X REQ PHY/QHP | 98 | $3,555 |
Drugs they prescribed that Part D paid
$14,926
Pharmacies billed $14,926 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 166) in 2024. At or below the middle of the specialty; the typical ophthalmology clinician is at 0%.
102 generic and 64 brand-name prescriptions · $14,926 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Difluprednate | 16 | $980 | $61 |
| Prednisolone Acetate | 12 | $921 | $77 |
| Dorzolamide-Timolol | 23 | $523 | $23 |
| Latanoprost | 51 | $483 | $9 |
| Brimonidine | 14 | $177 | $13 |
Year by year
| 2024 | 166 | 50 | 0% (0) | 39% | $14,926 |
| 2023 | 157 | 49 | 0% (0) | 36% | $10,378 |
| 2022 | 127 | 36 | 0% (0) | 41% | $12,451 |
| 2021 | 233 | 57 | 0% (0) | 46% | $19,477 |
| 2020 | 141 | 46 | 0% (0) | 48% | $9,444 |
| 2019 | 158 | 42 | 0% (0) | 44% | $8,425 |
| 2018 | 165 | 45 | 0% (0) | 48% | $10,920 |
| 2017 | 209 | 40 | 0% (0) | 38% | $39,128 |
| 2016 | 173 | 43 | None | 38% | $10,525 |
| 2015 | 115 | 33 | 0% (0) | 56% | $34,510 |
| 2014 | 136 | 31 | None | 56% | $17,192 |
| 2013 | 145 | 38 | 0% (0) | 54% | $11,715 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 7 drugs
| Prednisolone Acetate | 23 | $1,776 | $77 |
| Difluprednate | 11 | $1,625 | $148 |
| Latanoprost | 40 | $977 | $24 |
| Atropine Sulfate | 11 | $899 | $82 |
| Dorzolamide-Timolol | 23 | $525 | $23 |
| Brimonidine | 11 | $364 | $33 |
| Polymyxin B Sul-Trimethoprim | 13 | $118 | $9 |
2022: 4 drugs
| Latanoprost | 42 | $1,178 | $28 |
| Dorzolamide-Timolol | 22 | $1,134 | $52 |
| Brimonidine | 13 | $1,055 | $81 |
| Olopatadine | 14 | $598 | $43 |
2021: 7 drugs
| Brimonidine | 34 | $3,404 | $100 |
| Betimol | 15 | $2,386 | $159 |
| Prednisolone Acetate | 29 | $2,004 | $69 |
| Dorzolamide-Timolol | 36 | $1,419 | $39 |
| Latanoprost | 35 | $1,139 | $33 |
| Olopatadine | 12 | $526 | $44 |
| Dorzolamide | 11 | $331 | $30 |
2020: 6 drugs
| Prednisolone Acetate | 20 | $1,599 | $80 |
| Atropine Sulfate | 16 | $1,547 | $97 |
| Dorzolamide-Timolol | 21 | $861 | $41 |
| Brimonidine | 18 | $735 | $41 |
| Latanoprost | 18 | $642 | $36 |
| Polymyxin B Sul-Trimethoprim | 17 | $157 | $9 |
2019: 7 drugs
| Durezol | 15 | $2,931 | $195 |
| Prednisolone Acetate | 21 | $1,600 | $76 |
| Atropine Sulfate | 14 | $1,356 | $97 |
| Latanoprost | 21 | $430 | $20 |
| Dorzolamide-Timolol | 11 | $293 | $27 |
| Polymyxin B Sul-Trimethoprim | 20 | $185 | $9 |
| Brimonidine | 12 | $147 | $12 |
2018: 5 drugs
| Durezol | 14 | $2,489 | $178 |
| Brimonidine | 27 | $1,367 | $51 |
| Prednisolone Acetate | 18 | $993 | $55 |
| Latanoprost | 23 | $307 | $13 |
| Dorzolamide-Timolol | 12 | $229 | $19 |
2017: 6 drugs
| Brimonidine | 24 | $2,638 | $110 |
| Prednisolone Acetate | 22 | $1,581 | $72 |
| Latanoprost | 44 | $539 | $12 |
| Dorzolamide-Timolol | 27 | $412 | $15 |
| Polymyxin B Sul-Trimethoprim | 13 | $100 | $8 |
| Timolol Maleate | 15 | $98 | $7 |
2016: 3 drugs
| Prednisolone Acetate | 18 | $1,239 | $69 |
| Latanoprost | 26 | $354 | $14 |
| Polymyxin B Sul-Trimethoprim | 16 | $127 | $8 |
2015: 3 drugs
| Patanol | 11 | $2,647 | $241 |
| Prednisolone Acetate | 20 | $1,929 | $96 |
| Latanoprost | 21 | $237 | $11 |
2014: 6 drugs
| Brimonidine | 17 | $1,746 | $103 |
| Travatan Z | 11 | $1,215 | $110 |
| Prednisolone Acetate | 12 | $1,178 | $98 |
| Dorzolamide-Timolol | 12 | $315 | $26 |
| Latanoprost | 12 | $178 | $15 |
| Polymyxin B Sul-Trimethoprim | 11 | $104 | $9 |
2013: 2 drugs
| Prednisolone Acetate | 30 | $833 | $28 |
| Polymyxin B Sul-Trimethoprim | 21 | $227 | $11 |
Money from drug and device companies
$5,679 in 2025
| 2025 | 2 | 4 | $5,400 | $5,679 |
| 2024 | 5 | 10 | None | $1,336 |
| 2023 | 4 | 5 | $4,200 | $4,433 |
| 2022 | 4 | 4 | None | $3,127 |
| 2021 | 2 | 3 | None | $2,571 |
| 2019 | 2 | 3 | None | $372 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Sun Pharmaceutical Industries | None | $5,400 | 1 payment
|
| Regeneron Healthcare Solutions | Eylea Hd | $279 | 3 payments
|
See all 4 published payments
| Regeneron Healthcare Solutions | Meals · 2025-11-15 | Eylea Hd | $118 |
| Regeneron Healthcare Solutions | Meals · 2025-10-02 | Eylea Hd | $28 |
| Sun Pharmaceutical Industries | Consulting · 2025-09-18 | None | $5,400 |
| Regeneron Healthcare Solutions | Meals · 2025-02-05 | Eylea Hd | $134 |
See earlier years (2024, 2023, 2022, 2021, 2019)
2024: $1,336
| Alcon Vision | Constellation | $417 | 3 payments
|
| Harrow Eye | Iheezo | $349 | 3 payments
|
| Dutch Ophthalmic USA | Eva, Combined Machine | $327 | 2 payments
|
| Bausch & Lomb Americas | Xipere | $139 | 1 payment
|
| Apellis Pharmaceuticals | Syfovre | $103 | 1 payment
|
2023: $4,433
| Genentech USA | Vabysmo | $4,310 | 2 payments
|
| Apellis Pharmaceuticals | Syfovre | $74 | 1 payment
|
| Astellas Pharma US | None | $25 | 1 payment
|
| Regeneron Healthcare Solutions | Eylea | $24 | 1 payment
|
2022: $3,127
| Alcon Vision | None | $2,804 | 1 payment
|
| Genentech USA | Vabysmo | $126 | 1 payment
|
| Regeneron Healthcare Solutions | Eylea | $116 | 1 payment
|
| Alimera Sciences | Iluvien | $81 | 1 payment
|
2021: $2,571
| Alcon Vision | None | $2,450 | 2 payments
|
| Regeneron Healthcare Solutions | Eylea | $121 | 1 payment
|
2019: $372
| Genentech USA | Lucentis | $261 | 2 payments
|
| Alcon Vision | None | $111 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Genentech, Inc. · Port Delivery System of Ranibizumab Extension Study · 2022 | Their institution | $159,407 |
| Genentech, Inc. · Port Delivery System for Ranibizumab · 2019 | Their institution | $103,652 |
| Genentech, Inc. · Port Delivery System of Ranibizumab Extension Study · 2021 | Their institution | $88,015 |
| Genentech, Inc. · Port Delivery System for Ranibizumab · 2021 | Their institution | $81,293 |
| Genentech, Inc. · Port Delivery System for Ranibizumab · 2020 | Their institution | $80,018 |
| Genentech, Inc. · Port Delivery System of Ranizibumab Extension Study · 2019 | Their institution | $41,617 |
| Genentech, Inc. · Lucentis Fsv4 Lad Amd Ladder · 2019 | Their institution | $41,047 |
| Genentech, Inc. · Port Delivery System of Ranibizumab Extension Study · 2024 | Their institution | $39,910 |
| Genentech, Inc. · Port Delivery System of Ranibizumab Extension Study · 2023 | Their institution | $33,473 |
| Genentech, Inc. · Port Delivery System of Ranizibumab Extension Study · 2020 | Their institution | $32,613 |
| Genentech, Inc. · Port Delivery System of Ranizibumab Extension Study · 2021 | Their institution | $23,390 |
| ABBVIE INC. · Long-Term Follow-Up Study of Rgx-314 and Fellow Eye Substudy (Rgx-314 Srltfu) · 2025 | Their institution | $14,664 |
| Genentech, Inc. · Lucentis Fsv4 Lad Amd Ladder · 2020 | Their institution | $13,025 |
| F. Hoffmann-La Roche AG · Clinical Trial Versus Real-World Outcomes With Anti-Vascular Endothelial Growth Factor Therapy for Central Retinal Vein Occlusion · 2020 | This clinician | $6,979 |
| Genentech, Inc. · Port Delivery System of Ranibizumab Extension Study · 2025 | Their institution | $5,742 |
| ABBVIE INC. · Long-Term Follow-Up Study of Rgx-314 and Fellow Eye Substudy · 2025 | Their institution | $2,222 |
| F. Hoffmann-La Roche AG · Heterogeneity Among Patients With Retinal Vein Occlusion Relationship Between Injection Need and Vision Outcomes With As-Needed Ranibizumab · 2022 | This clinician | $1,604 |
| F. Hoffmann-La Roche AG · Clinical Trial Versus Real-World Outcomes With Anti-Vegf Therapy for Central Retinal Vein Occlusion · 2020 | This clinician | $850 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 75.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1831138676
- Licence
- CA G84511California G84511: Current · expires 2028-03-31
- Trained
- Stanford University School of Medicine, 1992 · 34 years ago
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 00G845110
- Taxonomy
- Federal specialty code 207W00000X (207W00000X)
- Mailing address
- 1635 Divisadero Street, Suite 625, Box 1821, San Francisco, CA, 94143
- NPI first listed
- 2006-06-06
- NPI last updated
- 2008-07-21
This is when the NPI record was last certified, not a medical board exam.